Mercer Global Advisors
NTLA icon

Mercer Global Advisors’s Intellia Therapeutics NTLA Stock Holding History

Mercer Global Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
20,910
+881
+4% +$12.3K ﹤0.01% 2632
2026
Q1 		$257K Buy
20,029
+10,000
+100% +$127K ﹤0.01% 2589
2025
Q4 		$90.2K Buy
+10,029
New +$138K ﹤0.01% 2735

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Mercer Global Advisors's NTLA Position: Q2 2026 in Review

Mercer Global Advisors increased its Intellia Therapeutics (NTLA) stake by 4.4% in Q2 2026, buying an estimated $12.3K and bringing the position to 20,910 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Mercer Global Advisors first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Mercer Global Advisors held 20,910 shares of Intellia Therapeutics worth $354K as of Q2 2026.
  • Mercer Global Advisors bought 881 Intellia Therapeutics shares in Q2 2026, an estimated $12.3K.
  • Intellia Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2632 holding.
  • Mercer Global Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.